Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-HA-2 TCR-engineered T cells TSC-101

A preparation of donor-derived T lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for HLA-A*02:01-restricted minor histocompatibility antigen HA-2 (HA2), with potential immunomodulating and antineoplastic activities. Following allogeneic haploidentical hematopoietic cell transplantation (HCT) in HLA-A*02:01 positive patients, allogeneic anti-HA-2 TCR-engineered T cells TSC-101 specifically recognize and bind to HA-2 expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing HA-2. HA-2 is a lineage-specific antigen found on leukemia cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic T-cell receptor-engineered T cells TSC-101
HA-2-targeting TCR-T cells TSC-101
T-cell receptor engineered donor T Cells TSC-101
Code name:TSC 101
TSC-101
TSC101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search